Generic anticancers prop up first-half pharma sales at Nippon Kayaku
This article was originally published in Scrip
Executive Summary
Pharmaceutical sales at Nippon Kayaku in Japan slipped by around 1% to ¥24.9 billion ($302.7 million) in the first half ended 30 November, hit by weakness for mainstay branded anticancer products.